Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial (Q34634936)

3 August 2017

Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial (English)

1 reference

3 August 2017

phase III clinical trial

0 references

0 references

1 reference

1 reference

Young-Woo Kim

2

0 references

Jiafu Ji

object named as

Jiafu Ji

13

0 references

Hyun Cheol Chung

object named as

Hyun Cheol Chung

4

1 reference

ORCID Public Data File 2021

Yung-Jue Bang

1

object named as

Yung-Jue Bang

1 reference

3 August 2017

12

Yeul Hong Kim

1 reference

3 August 2017

Han-Kwang Yang

3

1 reference

3 August 2017

Young-Kyu Park

5

1 reference

3 August 2017

Kyung Hee Lee

6

1 reference

3 August 2017

Keun-Wook Lee

7

1 reference

3 August 2017

Yong Ho Kim

8

1 reference

3 August 2017

Sang-Ik Noh

9

1 reference

3 August 2017

Jae Yong Cho

10

1 reference

3 August 2017

Young Jae Mok

11

1 reference

3 August 2017

Ta-Sen Yeh

14

1 reference

3 August 2017

Peter Button

15

1 reference

3 August 2017

Florin Sirzén

16

1 reference

3 August 2017

Sung Hoon Noh

17

1 reference

3 August 2017

CLASSIC trial investigators

18

1 reference

3 August 2017

language of work or name

English

0 references

publication date

7 January 2012

1 reference

3 August 2017

1 reference

3 August 2017

379

1 reference

3 August 2017

315-321

1 reference

3 August 2017

9813

1 reference

Updates on esophageal and gastric cancers

3 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961873-4

7 January 2021

Gastric cancer--patterns of relapse after surgical resection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961873-4

7 January 2021

Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Co-operative Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961873-4

7 January 2021

Extended lymph-node dissection for gastric cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961873-4

7 January 2021

Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961873-4

7 January 2021

Nodal dissection for patients with gastric cancer: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961873-4

7 January 2021

Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961873-4

7 January 2021

Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961873-4

7 January 2021

Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961873-4

7 January 2021

Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961873-4

7 January 2021

Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961873-4

7 January 2021

Overview of adjuvant therapy for resected gastric cancer: differences in Japan and the United States

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961873-4

7 January 2021

Disparities in gastric cancer chemotherapy between the East and West

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961873-4

7 January 2021

Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961873-4

7 January 2021

Oxaliplatin and capecitabine in patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction and gastric cardia: a phase II study from the North Central Cancer Treatment Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961873-4

7 January 2021

Multicenter phase II study of capecitabine plus oxaliplatin as a first-line therapy in Chinese patients with advanced gastric cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961873-4

7 January 2021

Phase II trial of XELOX as first-line treatment for patients with advanced gastric cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961873-4

7 January 2021

Capecitabine in combination with Oxaliplatin (XELOX) as a first-line therapy for advanced gastric cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961873-4

7 January 2021

Investigation of the recurrence patterns of gastric cancer following a curative resection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961873-4

7 January 2021

Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961873-4

7 January 2021

Phase III Trial of Capecitabine Plus Oxaliplatin As Adjuvant Therapy for Stage III Colon Cancer: A Planned Safety Analysis in 1,864 Patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961873-4

7 January 2021

Comparison of gastric cancer survival following R0 resection in the United States and Korea using an internationally validated nomogram.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961873-4

7 January 2021

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961873-4

7 January 2021

10.1016/S0140-6736(11)61873-4

Identifiers

DOI

1 reference

release_qbanc4ib25dyrd5q3ni4p57rey

3 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/qbanc4ib25dyrd5q3ni4p57rey

24 November 2022

mapped directly with Wikidata item

1 reference